Cara Community Biotechs: BioNTech

BioNTech SE (NASDAQ: BNTX) reviewed 10-14-2020

Market Cap: $20.2 Billion (USD)                 Share Price: $86.86 (USD)

Shares outstanding: 232,304,000

Cash & cash equivalents: $519 M (Euro) at 30 June 2020

Debt:  $19.45 M (Euro) via Deutsche Bank AG

Insiders: 1.26%                  Institutional: 36 holders own approx. 4% of the float


Investor Presentations:

CEO: Ugur Sahin                HQs: Mainz, Germany

BioNTech was founded in 2008 to seek immunotherapy genetic treatments for cancer

The company is in collaboration, with Pfizer, since March 2020 to develop a COVID-19 vaccine

Focused on oncology with 20+ products in the pipeline; 10 are currently in clinical trials

Has 1300 employees and seven collaborative partnerships

Phase 1 Trials:

  • BNT111, BNT112, BNT113: Melanoma, Prostate cancer, Head & Neck cancers
  • BNT114, BNT115, BNT116: Breast cancer, ovarian cancer, and NSCLC
  • BNT122, BNT131: 1L Melanoma, Locally advanced or metastatic solid tumors, & solid tumors

Phase 3 trials:

  • BNT162: COVID-19 in Phase 3 development with Pfizer, and Fosun Pharmaceutical (China)

Collaboration: Pfizer, Genentech, Penn, Sanofi, Global, Genmab, Genevant

, mainly as a result of the COVID-19 vaccine collaboration with Pfizer

Bottom Line:

  • My top-pick Biotech stock is BioNTech, which is the Moderna of Germany and Europe.
  • I like the fact they collaborate with Pfizer for manufacturing scale by contributing multiple mRNA vaccine candidates as part of its leading BNT162 COVID-19 program. That has helped BNTX shares increase by 572% in the past year

Like to give your opinion? Join our Community Discussion